Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 1.26% 80.40 79.00 80.00 81.40 78.60 81.20 135,837 16:00:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.9 5.5 0.8 99.3 366

Ekf Diagnostics Share Discussion Threads

Showing 3126 to 3146 of 3350 messages
Chat Pages: 134  133  132  131  130  129  128  127  126  125  124  123  Older
DateSubjectAuthorDiscuss
26/2/2021
18:23
Tong performed like this on SDI. the day after he quit with with a flourish it shot up. Filter him.
petewy
26/2/2021
15:34
I note that earlier this week Novacyt announced the launch of its next generation high-throughput PCR test for COVID-19 (COVIDHT Direct), which has been CE Mark approved. • The new COVID-HT Direct uses pharyngeal swabs collected in viral transport media (without guanidine)and saline So this should be applicable to samples collected in PrimeStore ATM, which does not contain guanidine. I also note that it's extraction-free - 24th February 2021 Launch of CE Mark COVID-HT Direct Novacyt announces the launch of its next generation high-throughput PCR test for COVID19 (COVID-HT Direct), which has been CE Mark approved using independent validated data. This follows the launch of the Company’s first high-throughput PCR test for COVID19 (COVID-HT) in June 2020. The new test eliminates the need for automated extraction systems in a high-volume PCR laboratory, reducing processing time, cost and labour of testing by up to 30%. The new COVID-HT Direct uses pharyngeal swabs collected in viral transport media (without guanidine) and saline. COVID-HT Direct is already in use at one of the UK’s Lighthouse laboratories and is being validated for use with private highthroughput PCR laboratory partners. hTTps://novacyt.com/wp-content/uploads/2021/02/Novacyt-RD-Update-24.02.2021-correction-ENGLISH.pdf
wan
26/2/2021
14:59
He's not stupid. He's just a troll.
jsredbird
26/2/2021
14:08
Excellent timing Joe - ekf falling out of bed. Ah no!!!
tongosti
26/2/2021
14:05
Tong, I am convinced that there is only one reason why you are behaving like this. You are too thick for you own good. Market is down and smallcaps are being hit harder than usual. Maybe it has something to do with IGindex' new regs but I believe it is temporary. Please see a doctor about your mental health. We need to save you from your own stupidity.
mg1982
26/2/2021
11:14
Wan - what happened today fella? Can't take your eye off the ball chief ... come on!
tongosti
25/2/2021
12:29
Phew ... there he is.
tongosti
25/2/2021
07:18
In the news - DHL Global Forwarding Partners Longhorn Vaccines & Diagnostics to Assure Safety and Efficacy of Lab Testing in Africa and Asia By DHL, Media OutReach 25th February 2021 *DHL has transported nearly 26,000 Covid -19 testing vials for Longhorn, who is donating one million vials to the International Organization for Migration *Vials were transported via three initial flights from Indianapolis to Kenya, Nepal and the Philippines, supporting emerging markets in the process *Life-saving transports will help COVID-19 testing of refugees and displaced persons SINGAPORE - Media OutReach - 25 February 2021 - DHL Global Forwarding, the air and ocean freight specialist of Deutsche Post DHL Group, has partnered with Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, to deliver much-needed Covid-19 testing vials to the International Organization for Migration (IOM) in Kenya, Nepal and the Philippines. By DHL, Media OutReach "Once we coordinated the donation of one million PrimeStore® MTM sample collection devices with the IOM, we needed to manage the logistics of such a large endeavor," stated Jeff Fischer President of Longhorn Vaccines and Diagnostics. "PrimeStore® MTM inactivates SARS-CoV-2 during collection and transit, which can reduce the need for safety cabinets and reduce the time between collection and results. With the need to ship to different countries on multiple continents and traverse to varied customs requirements, DHL was the clear choice given the importance of reliable transportation in the testing process." Full release - hTTps://www.taiwannews.com.tw/en/news/4135878
wan
25/2/2021
06:31
1 hour to go Wan before your daily copy and paste.Countdown has started. 59 ... 58 .....
tongosti
24/2/2021
15:33
wait for it 'fellas'... You know what Tong is going to say right? He's long EKF from 64p (even though we never touched it) But those big trades today seem to have us going higher though
mg1982
24/2/2021
10:51
Quality copy and paste pal Any idea why the share price is being in Limbo for months? Ta. P.S. Told you fellas on the day this was way overdone but you wouldn't listen would you?
tongosti
24/2/2021
07:47
Sounds familiar - Siemens Healthineers offers lab-based antigen test for high-throughput analyzers and expands Covid-19 test capacities Erlangen, Germany 2021-02-23 The Siemens Healthineers SARS-CoV-2 Antigen Assay (CoV2Ag) offers an accurate, high-capacity testing solution to diagnose COVID-19. CoV2Ag offers testing for current infection worldwide on a widely available installed base of automated immunoassay analyzers. The fast time-to-result includes a pretreatment process to inactivate the virus as a safeguard for laboratory staff handling the samples. Siemens Healthineers announced today the company's laboratory-based SARS-CoV-2 Antigen Assay (CoV2Ag)1 obtained CE Mark and is now offered for the Atellica® Solution and ADVIA Centaur® analyzers, widely available in laboratories worldwide. The test has been submitted to the FDA for Emergency Use Authorization. The antigen test detects the nucleocapsid antigen and has been designed with five monoclonal antibodies with the objective to maximize its sensitivity to both current and future SARS-CoV-2 variants. It also offers a leading time-to-result for lab-based antigen tests, making it an ideal tool to test large quantities of patient samples quickly. Such testing could be deployed at on-site collection centers for hospital staff, patients and visitors, remote collection facilities for large scale testing of local populations or in dedicated, pop-up labs at airports or universities. In addition to speed and reliability, the test is further characterized by a pretreatment process that helps protect laboratory staff from the virus. It inactivates the virus without compromising the quality or validity of patient test results. Full release - hTTps://www.siemens-healthineers.com/press-room/press-releases/covid-19-lab-based-antigentest Is the pre-treatment process a Longhorn product? I am not sure at this stage, but what we can ascertain is that one of the largest diagnostic companies in the world, thinks that inactivation is an important part of the testing process (watch this space!). And provides food for thought while we await further details of how PrimeStore ATM will be utilised in antigen testing, and whether any Longhorn products manufactured by EKF make their way into rapid tests.
wan
23/2/2021
09:47
Edits to the above post....just a few tweaks and specifically that PrimeStore MTM is 'already' FDA approved.
wan
23/2/2021
09:30
Apparently, there is a view that testing will peak in Q1, so I guess that's why we have a pullback, along with most stocks associated with testing. The next thing the market will be trying to assess is for how long and at what level testing, including surveillance and genomic testing, will last. Chris Whitty (UK Chief Medical Officer), stated yesterday that Covid-19 will be with us for at least the next few winters. So, as we enter the autumn periods respectively, another key point will be testing to differentiate between flu and coronavirus. Not to mention that an important aspect of testing, will be that 'any type of test' is 'not' impacted by mutations (the FDA has just release guidance in this regard). In my view, PCR testing will endure for all of 2021 and into early 2022, so it's just a case of at what level. And importantly, the effect from the withdrawal of EUA's, that could focus demand onto PrimeStore MTM (which is 'already' FDA approved!), including (given the attributes) certain intuitions choosing to use only PrimeStore MTM, especially with regard to both surveillance and surge testing. And then how much surveillance testing is conducted globally, which is being ramped up significantly, and is now likely to be required forever! Rapid testing, and in that I am including rapid PCR testing, appears to have potential for very high volumes to at least be maintained, and possibly to grow significantly. In this regard, apart from Longhorn implying that they have been working with a large diagnostic player to use certain Longhorn ingredients to address rapid testing, we don't have much else to suggest EKF could enter the rapid Covid-19 testing market, but I am optimistic, given how EKF and Longhorn has been put on the map so to speak, that new products (including ATM) might give further exposure beyond PCR testing. Time will tell, but as a nod to some, personally I wouldn't want to be either short, or indeed out of EKF if that gets announced!
wan
23/2/2021
09:06
Yeah yeah yeah. The tape seems to indicate that if a strong close below 63 takes place, then the next step will v probably be another leg south to 45 level.
tongosti
19/2/2021
13:41
https://t.co/Xgpv9du0Gj?amp=1 Time lapse video of fit out at warp speed
mirandaj
19/2/2021
09:56
Rivaldo...Thanks for the SBI input, especially the significant increase in PCR testing since January. I guess that that fits well with the last Trading Update from EKF, which also stated - "Trading in the core business in the final quarter has continued to improve significantly and ongoing demand for the PrimeStore MTM COVID-19 sample collection device remained strong through to the end of the year and will continue to do so into the first quarter of 2021." "With continued strong performance in the core business and a number of indicative orders for PrimeStore MTM for the first quarter 2021 that are likely to be realised, the Board is confident that performance for the first quarter of 2021 will be materially ahead of current management expectations, and the first quarter of 2020." hTTps://www.ekfdiagnostics.com/trading-update12.html SBI's significant increase in testing appears, on the face of it, to endorse EKF's confidence in outperforming expectations.
wan
19/2/2021
09:12
Recall that back in September, I highlighted that Longhorns President confirmed in an interview that Longhorn was working with a diagnostic company to add PrimeStore MTM/ATM (or other certain ingredients) to their point of care test that differentiates between COVID-19 and flu. Also, I raised a question at an EKF zoom meeting regarding PrimeStore being compatible with saliva samples, which CEO Julian Baines said they were working on. And at the time I reported that Julian's answer gives me hope that a rapid test (quicker than current PCR) that specifically utilises PrimeStore (MTM or ATM) might not be too far off. And that in the same meeting, unfortunately my follow-up question regarding current and emerging LAMP test compatibility, appeared to run out of time for answering. And not to mention that, in any regard, that samples collected in transport media that does not inactivate the virus, are therefore still considered infectious and must be transferred in a biological safety cabinet and inactivation etc, significantly slowing down the work flow, which hardly seems compatible with mobile/pop-up laboratories.
wan
19/2/2021
08:33
Good spot wan. As a holder of SBI I've also given EKF a small plug on that bb :o)) I note that today's RNS states that "SourceBio has processed approaching 1,000,000 COVID-19 antigen RT-PCR tests for the DHSC and the NHS". SBI's 18th January trading statement noted that they had carried out 400,000 such tests. Which implies that in the month since then, SBI have carried out 600,000 new tests....which I assume will have utilised PrimeStore transportation devices?
rivaldo
19/2/2021
08:14
What I can confirm is that one of the components contained in PrimeStore MTM is guanidine isothiocynate. And I note that in the Rapid Evaluation Report that the analytical sensitivity for the LamPORE assay was evaluated using a blinded panel of guanidine isothiocynate inactivated SARS-CoV-2 virus.
wan
19/2/2021
07:59
Recall that an inactivation step is required for PCR type tests. However, this inactivation process is not required when using PrimeStore MTM
wan
Chat Pages: 134  133  132  131  130  129  128  127  126  125  124  123  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 15:16:23